Antibody-based Cancer Drugs

Developing Antibody Therapeutic approaches to deliver individualised cancer drugs

Date: March 15, 2005

Venue: Radisson SAS Scandinavia Hotel

City: Copenhagen, Denmark

In the Chair:

Dr. Terje Kalland
Senior Vice President Research & Development and Chief Scientific Officer
BIOVITRUM

Hear from your eminent Speaker Panel:

Dr. Geoffrey Davis
Chief Scientific Officer
ABGENIX (USA)

Professor Jan G. J. van de Winkel
Executive Vice President and Chief Scientific Officer
GENMAB

Dr. Roland Carlsson
Vice President Preclinical Research
BIOINVENT

Dr. Hans de Haard
Scientific Director
ABLYNX

Dr. Associate Professor Göran Forsberg
Head of Department Scientific Affairs
ACTIVE BIOTECH

Professor Peter Vollmers
Co-founder
ONCOMAB

Event Summary:

Oncology is the most active area in the pharmaceutical community driven by cancer as the leading cause of death in Western countries. Antibodies hold most promise in the treatment of cancer. By exploring antibody therapeutic approaches the number of target pathways increases significantly.

The vision of cancer immunology is to find new approaches to fighting cancer by activating the human body’s immune defence system. With antibodies as drugs the immune systems are able to attack the antigens which are found on the surface of cancer cells. Innovative biopharmaceuticals who successfully creates targeted antibody therapies to improve cancer patients’ health will be the winners of the future.

We are quickly moving in the direction where it is possible to develop the right drug to match with the right cancer patient. In tomorrow’s Bio-Society individual cancer medicines will be a reality!

This international one day symposium will examine the role of antibodies as new drugs for cancer in the future. The event provides you with a platform to design new antibody approaches for individualised cancer drugs with first-hand experiences learnt from the pioneers of oncology in the 21st century.

Key issues:

Focusing on antibodies as new drugs for Cancer
How to develop an antibody development platform in collaboration with partners
Understanding the biology of cancer to explore antibody therapeutic approaches
How to accelerate your drug discovery process through human monoclonal antibodies
Identifying anti-cancer agents to create novel concept for immunotherapy of Cancer
How to establish a regulatory framework to accelerate the innovation of cancer therapies
Creating a structure-based drug design to speed up the delivery of your antibody cancer drugs to the market
Developing personalised cancer drugs to tailor the treatment of various Cancer tumours

Target audience:

Presidents, Chief Executive Officers, Chief Scientific Officers, Chief Business Officers, Vice Presidents, Directors, Heads and Scientists within:

Biology
Cancer Research
Immunology
Antibody Technology
Oncology Discovery
Clinical Research
Biological Engineering
Research & Development
Oncology Research
Molecular Oncology
Cardiovascular, Oncology and Immunology
Science & Technology
Oncology Therapeutic Area
Global Oncology Development
New Therapies
Molecular Biology
Oncology Drug Development
Antibody Development
Business Development